- Home
- KF vs CYBN Comparison
KF vs CYBN Comparison
Compare KF & CYBN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KF
- CYBN
- Stock Information
- Founded
- KF 1984
- CYBN 2019
- Country
- KF United States
- CYBN Canada
- Employees
- KF N/A
- CYBN N/A
- Industry
- KF Investment Managers
- CYBN Pharmaceuticals and Biotechnology
- Sector
- KF Finance
- CYBN Health Care
- Exchange
- KF Nasdaq
- CYBN Nasdaq
- Market Cap
- KF 128.4M
- CYBN 147.4M
- IPO Year
- KF N/A
- CYBN N/A
- Fundamental
- Price
- KF $36.21
- CYBN $7.23
- Analyst Decision
- KF
- CYBN Strong Buy
- Analyst Count
- KF 0
- CYBN 3
- Target Price
- KF N/A
- CYBN $85.00
- AVG Volume (30 Days)
- KF 18.4K
- CYBN 988.4K
- Earning Date
- KF 01-01-0001
- CYBN 11-12-2025
- Dividend Yield
- KF N/A
- CYBN N/A
- EPS Growth
- KF N/A
- CYBN N/A
- EPS
- KF N/A
- CYBN N/A
- Revenue
- KF N/A
- CYBN N/A
- Revenue This Year
- KF N/A
- CYBN N/A
- Revenue Next Year
- KF N/A
- CYBN N/A
- P/E Ratio
- KF N/A
- CYBN N/A
- Revenue Growth
- KF N/A
- CYBN N/A
- 52 Week Low
- KF $18.30
- CYBN $4.81
- 52 Week High
- KF $25.56
- CYBN $13.88
- Technical
- Relative Strength Index (RSI)
- KF 77.02
- CYBN 62.87
- Support Level
- KF $35.67
- CYBN $6.86
- Resistance Level
- KF $36.50
- CYBN $8.00
- Average True Range (ATR)
- KF 0.59
- CYBN 0.41
- MACD
- KF 0.25
- CYBN 0.16
- Stochastic Oscillator
- KF 100.00
- CYBN 66.16
About KF Korea Fund Inc. (The) New
Korea Fund Inc is a closed-end, non-diversified management investment company. Its investment objective is to seek long-term capital appreciation through investment in securities, equity securities, of Korean companies. Its portfolio consists of the different sectors such as the auto components, banks, beverages, chemicals, aerospace and defense, insurance, machinery, and Others.
About CYBN Cybin Inc.
Cybin Inc is a biopharmaceutical company involved in creating safe and effective therapeutics for patients to address a multitude of mental health issues. The Company is a clinical-stage neuropsychiatric company focused on advancing therapies, delivery mechanisms, novel compounds, and protocols as potential treatments for various psychiatric and neurological conditions. The Company is developing technologies and delivery systems aimed at improving the pharmacokinetics of its proprietary molecules while retaining the therapeutic benefit. These new molecules and delivery systems are expected to be studied through clinical trials to confirm safety and efficacy.